Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rang in aandelen #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Aandeelprijs
$5.54
Laatst gesynchroniseerd: 2024-09-18
Marktkapitalisatie
$38.76M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Alimera Sciences, Inc. (ALIM)

Categorie

EPS voor Alimera Sciences, Inc. (ALIM)
EPS per June 2024 TTM: $-0.28
Volgens de laatste financiële rapporten en de aandelenkoers van Alimera Sciences, Inc. is de huidige EPS van het bedrijf (TTM) $-0.28. Eind 2022 had het bedrijf een EPS van $-2.59, een stijging ten opzichte van de EPS van 2021 die $-0.66 bedroeg.
EPS-geschiedenis van Alimera Sciences, Inc. van 2006 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) $-0.28 -64.56%
2023 $-0.79 -69.50%
2022 $-2.59 292.42%
2021 $-0.66 -36.54%
2020 $-1.04 -52.51%
2019 $-2.19 -158.40%
2018 $3.75 -176.06%
2017 $-4.93 -47.66%
2016 $-9.42 -8.90%
2015 $-10.34 -22.43%
2014 $-13.33 -45.14%
2013 $-24.30 158.24%
2012 $-9.41 -12.63%
2011 $-10.77 61.95%
2010 $-6.65 -98.48%
2009 $-437.12 -23.24%
2008 $-569.46 977.30%
2007 $-52.86 -56.02%
2006 $-120.18 0.00%
EPS van vergelijkbare bedrijven of concurrenten